Latest News
MannKind Corporation
- MannKind Corporation Estimates – FWB:NNFN
- What Are the Next Clinical Catalysts for Rapport (NASDAQ:RAPP), Praxis (NASDAQ:PRAX) and MannKind (NASDAQ:MNKD)?
- Why Is MannKind (NASDAQ:MNKD) Down 2.90% Near USD 3.10?
- MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
- MannKind at Chardan’s 10th Annual Healthcare Conference: pipeline broadens
- Chardan initiates MannKind stock coverage with buy rating on pipeline By Investing.com
- This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- MannKind CEO to join panel on chronic respirato...
- MannKind to Participate in the Chardan Healthcare Conference
- MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
- MannKind Corporation (MNKD) Slides 3.80% to $3.80 as Shares Drift Toward Lower Support - Market Cap Weight
- Steven Binder sells $128,477 of MannKind (MNKD) stock
Headlines from the last 30 days, linking to the original publishers. See all market news →